Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Weapon for Fighting Antibiotic Drug Resistance

12.08.2003


The most important antibiotics in general use today are the b-lactam family of products, but the medical community faces a serious problem with these antibiotics: the increasing development of drug resistance. The resistance is caused by hydrolysis of the b-lactam by a bacterial lactamase enzyme, but fortunately it can often be overcome by the use of a serine b-lactamase inhibitor in combination with the drug. This approach is successfully used already, for example clavulanic acid is used in combination with amoxycillin in Augmentin.



Unfortunately, various b-lactam drugs are also inactivated by metallo-b-lactamases, which cannot be overcome by the current range of serine b-lactamase inhibitors. Until recently, there have been no metallo-b-lactamase inhibitors of any kind to protect the drugs from this type of resistance.

Researchers at Oxford University’s Department of Chemistry now believe they have found a solution to this problem. They have discovered a new class of inhibitors of Class B bacterial lactamases, which are responsible for the hydrolysis of many antibiotics and hence drug resistance in those bacteria.


The researchers identified a number of potentially useful inhibitor compounds, which are mainly perfluoroalkyl derivatives of a-amino acids or a peptide, made by either conventional routes or by a novel method involving oxazolidinone formation, silylation and desilylation with ring cleavage. Assays for inhibition were carried out using the published procedures of Walter et al to yield inhibition constants, and kinetic data is also available for certain compounds.

The new metallo-b-lactamase inhibitors provide an attractive alternative approach to enhancing antibiotic performance and overcoming antibiotic resistance in bacteria.

Isis Innovation, Oxford’s technology transfer company, holds a granted patent on this novel technology and welcomes contact from companies interested in commercially developing this technology for the drug industry.

Jennifer Johnson | alfa
Further information:
http://www.isis-innovation.com/licensing/29.html

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>